Compare Stocks

Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities.

Comparative Price Performance Over Time

Compare Price & Volume

Company	Current Price	50-Day Moving Average	52-Week Range	Market Cap	Beta	Avg. Volume	Today's Volume
DSGN Design Therapeutics	$3.97 +1.8%	$3.85	$2.60 ▼ $7.77	$221.40M	1.62	180,966 shs	130,626 shs
ESPR Esperion Therapeutics	$1.07 +2.9%	$0.97	$0.69 ▼ $3.94	$206.13M	0.67	5.17 million shs	2.57 million shs
IFRX InflaRx	$0.80 +0.9%	$1.25	$0.71 ▼ $2.82	$53.24M	1.29	286,078 shs	131,633 shs
NBTX Nanobiotix	$4.41 -0.2%	$3.94	$2.76 ▼ $6.00	$208.09M	0.36	15,663 shs	2,573 shs

Options Trading Made Easy - Download Now

Learn the basics of options trading and how to use them to boost returns and manage risk with this free report from MarketBeat. Click the link below to get your free copy.

Get This Free Report

Compare Price Performance

Company	1-Day Performance	7-Day Performance	30-Day Performance	90-Day Performance	1-Year Performance
DSGN Design Therapeutics	+1.79%	+7.88%	+4.20%	-4.34%	+18.15%
ESPR Esperion Therapeutics	+2.88%	-1.83%	+35.39%	-34.36%	-50.92%
IFRX InflaRx	+0.88%	+3.91%	-56.76%	-35.48%	-52.10%
NBTX Nanobiotix	-0.88%	-4.23%	+16.08%	+28.57%	+1.15%

Compare MarketRank™

Company	Overall Score	Analyst's Opinion	Short Interest Score	ESG Score	News and Social Media Sentiment	Company Ownership	Earnings & Valuation
DSGN Design Therapeutics	0.3693 of 5 stars	1.0	1.0	0.0	0.6	2.5	0.6
ESPR Esperion Therapeutics	4.1295 of 5 stars	3.4	3.0	3.9	2.4	1.7	0.6
IFRX InflaRx	2.7543 of 5 stars	3.5	3.0	0.0	2.6	1.7	0.6
NBTX Nanobiotix	2.2258 of 5 stars	3.3	5.0	0.0	1.1	0.0	0.6

Compare Analyst Forecasts

Company	Consensus Rating Score	Consensus Rating	Consensus Price Target	% Upside from Current Price
DSGN Design Therapeutics	2.00	Hold	$4.00	0.76% Upside
ESPR Esperion Therapeutics	2.80	Moderate Buy	$7.00	554.21% Upside
IFRX InflaRx	3.00	Buy	$6.60	725.00% Upside
NBTX Nanobiotix	2.50	Moderate Buy	$8.00	81.41% Upside

Current Analyst Ratings Breakdown

Latest IFRX, DSGN, ESPR, and NBTX Analyst Ratings

Date	Company	Brokerage	Action	Rating	Price Target
6/17/2025	ESPR Esperion Therapeutics	HC Wainwright Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Buy ➝ Buy	$16.00
5/29/2025	IFRX InflaRx	Raymond James Financial Subscribe to MarketBeat All Access for the recommendation accuracy rating	Downgrade	Strong-Buy ➝ Outperform	$2.00
5/29/2025	IFRX InflaRx	Oppenheimer Subscribe to MarketBeat All Access for the recommendation accuracy rating	Lower Price Target	Outperform ➝ Outperform	$6.00 ➝ $3.00
5/8/2025	IFRX InflaRx	Oppenheimer Subscribe to MarketBeat All Access for the recommendation accuracy rating	Initiated Coverage	Outperform	$6.00
5/7/2025	ESPR Esperion Therapeutics	Needham & Company LLC Subscribe to MarketBeat All Access for the recommendation accuracy rating	Lower Price Target	Buy ➝ Buy	$5.00 ➝ $4.00
4/29/2025	IFRX InflaRx	Cantor Fitzgerald Subscribe to MarketBeat All Access for the recommendation accuracy rating	Initiated Coverage	Overweight	$10.00
4/25/2025	ESPR Esperion Therapeutics	Needham & Company LLC Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Buy ➝ Buy	$5.00 ➝ $5.00
4/25/2025	ESPR Esperion Therapeutics	HC Wainwright Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Buy ➝ Buy	$16.00 ➝ $16.00
4/17/2025	ESPR Esperion Therapeutics	The Goldman Sachs Group Subscribe to MarketBeat All Access for the recommendation accuracy rating	Lower Price Target	Neutral ➝ Neutral	$4.00 ➝ $3.00
4/8/2025	ESPR Esperion Therapeutics	Needham & Company LLC Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Buy ➝ Buy	$5.00 ➝ $5.00
4/4/2025	NBTX Nanobiotix	Guggenheim Subscribe to MarketBeat All Access for the recommendation accuracy rating	Lower Price Target	Buy ➝ Buy	$12.00 ➝ $8.00

(Data available from 6/25/2022 forward. View 10+ years of historical ratings with our analyst ratings screener.)

Compare Sales & Book Value

Company	Annual Revenue	Price/Sales	Cashflow	Price/Cash	Book Value	Price/Book
DSGN Design Therapeutics	N/A	N/A	N/A	N/A	$4.28 per share	N/A
ESPR Esperion Therapeutics	$332.31M	0.64	$0.02 per share	43.29	($1.97) per share	-0.54
IFRX InflaRx	$180K	298.36	N/A	N/A	$1.13 per share	0.71
NBTX Nanobiotix	$39.18M	5.30	N/A	N/A	($1.51) per share	-2.92

Compare Profitability & Earnings

Company	Net Income	EPS	Trailing P/E Ratio	Forward P/E Ratio	P/E Growth	Net Margins	Return on Equity (ROE)	Return on Assets (ROA)	Next Earnings Date
DSGN Design Therapeutics	-$49.59M	-$0.99	N/A	N/A	N/A	N/A	-22.85%	-22.02%	8/4/2025 (Estimated)
ESPR Esperion Therapeutics	-$51.74M	-$0.80	N/A	N/A	N/A	-59.03%	-0.91%	-29.47%	8/11/2025 (Estimated)
IFRX InflaRx	-$49.85M	-$0.82	N/A	N/A	N/A	-33,362.70%	-64.17%	-53.39%	8/6/2025 (Estimated)
NBTX Nanobiotix	-$73.73M	N/A	0.00	N/A	N/A	N/A	N/A	N/A	N/A

Latest IFRX, DSGN, ESPR, and NBTX Earnings

Date	Quarter	Company	Consensus Estimate	Reported EPS	Beat/Miss	Gap EPS	Revenue Estimate	Actual Revenue
5/14/2025	Q1 2025	DSGN Design Therapeutics	-$0.28	-$0.31	-$0.03	-$0.31	N/A	N/A
5/7/2025	Q1 2025	IFRX InflaRx	-$0.18	-$0.14	+$0.04	-$0.14	$0.03 million	$0.03 million
5/6/2025	Q1 2025	ESPR Esperion Therapeutics	-$0.18	-$0.21	-$0.03	-$0.21	$54.97 million	$65.00 million

Compare Dividends

Company	Annual Payout	Dividend Yield	3-Year Dividend Growth	Payout Ratio	Years of Consecutive Growth
DSGN Design Therapeutics	N/A	N/A	N/A	N/A	N/A
ESPR Esperion Therapeutics	N/A	N/A	N/A	N/A	N/A
IFRX InflaRx	N/A	N/A	N/A	N/A	N/A
NBTX Nanobiotix	N/A	N/A	N/A	N/A	N/A

Compare Debt

Company	Debt-to-Equity Ratio	Current Ratio	Quick Ratio
DSGN Design Therapeutics	N/A	28.37	28.37
ESPR Esperion Therapeutics	N/A	1.18	0.81
IFRX InflaRx	N/A	5.28	4.86
NBTX Nanobiotix	N/A	1.04	1.04

Compare Ownership

Institutional Ownership

Company	Institutional Ownership
DSGN Design Therapeutics	56.64%
ESPR Esperion Therapeutics	47.39%
IFRX InflaRx	42.39%
NBTX Nanobiotix	38.81%

Insider Ownership

Company	Insider Ownership
DSGN Design Therapeutics	31.20%
ESPR Esperion Therapeutics	1.70%
IFRX InflaRx	16.30%
NBTX Nanobiotix	3.45%

Compare Miscellaneous Stats

Company	Employees	Shares Outstanding	Free Float	Optionable
DSGN Design Therapeutics	40	56.77 million	39.06 million	Optionable
ESPR Esperion Therapeutics	200	198.20 million	194.83 million	Optionable
IFRX InflaRx	60	67.13 million	56.19 million	Optionable
NBTX Nanobiotix	100	47.13 million	45.51 million	Not Optionable

IFRX, DSGN, ESPR, and NBTX Headlines

Recent News About These Companies

Short Interest in Nanobiotix S.A. (NASDAQ:NBTX) Declines By 89.1%

June 11, 2025 | marketbeat.com

Nanobiotix (NASDAQ:NBTX) Stock Price Up 1.1% - Here's Why

June 4, 2025 | marketbeat.com

Short Interest in Nanobiotix S.A. (NASDAQ:NBTX) Grows By 1,197.9%

May 30, 2025 | marketbeat.com

NANOBIOTIX to Participate in the Jefferies Global Healthcare Investor Conference

May 28, 2025 | globenewswire.com

Nanobiotix Provides First Quarter 2025 Operational and Financial Update

May 21, 2025 | globenewswire.com

Nanobiotix to Participate in the H.C. Wainwright 3rd Annual BioConnect Investor Conference at NASDAQ

May 12, 2025 | globenewswire.com

Nanobiotix Reveals Favorable Results Of JNJ-1900 Study Pancreatic Cancer; Seeks Further Evaluation

May 5, 2025 | finanznachrichten.de

Nanobiotix Announces Full Results From Completed Phase 1 Study Evaluating JNJ-1900 (NBTXR3) in Pancreatic Cancer

May 5, 2025 | globenewswire.com

Nanobiotix Announces Presentation of Full Results From Completed Phase 1 Study Evaluating JNJ-1900 (NBTXR3) in Pancreatic Cancer Followed by a Conference Call

April 30, 2025 | globenewswire.com

Nanobiotix price target lowered to $8 from $12 at Guggenheim

April 5, 2025 | markets.businessinsider.com

Nanobiotix (NBTX) Gets a Hold from UBS

April 5, 2025 | markets.businessinsider.com

Nanobiotix S.A. (NBTX) Q4 2024 Earnings Call Transcript

April 3, 2025 | seekingalpha.com

NANOBIOTIX Provides Business Update and Reports Full Year 2024 Financial Results

April 2, 2025 | globenewswire.com

Analysts Have Conflicting Sentiments on These Healthcare Companies: Pfizer (PFE), Nanobiotix (NBTX) and PTC Therapeutics (PTCT)

April 2, 2025 | theglobeandmail.com

NANOBIOTIX to Announce Fourth Quarter and Full Year 2024 Operational and Financial Update on April 2, 2025

March 31, 2025 | globenewswire.com

Nanobiotix reports promising NSCLC treatment study results

March 29, 2025 | investing.com

Nanobiotix Announces First Data From the Completed Dose Escalation Part of a Phase 1 Study Evaluating NBTXR3 (JNJ-1900) as a 2L+ Therapy for Patients With Locally Advanced NSCLC

March 27, 2025 | globenewswire.com

NANOBIOTIX Announces Presentation of Data From Two Phase 1 Studies Evaluating JNJ-1900 (NBTXR3)

March 21, 2025 | djournal.com

NANOBIOTIX Announces Presentation of Data From Two Phase 1 Studies Evaluating JNJ-1900 (NBTXR3) at the European Lung Cancer Conference

March 20, 2025 | globenewswire.com

Nanobiotix amends global licensing agreement with Janssen Pharmaceutica

March 18, 2025 | markets.businessinsider.com

NANOBIOTIX Strengthens Financial Position Through Amendment of Global Licensing Agreement for JNJ-1900 (NBTXR3) and Extends Cash Visibility to Mid-2026

March 17, 2025 | globenewswire.com

New MarketBeat Followers Over Time

Media Sentiment Over Time

IFRX, DSGN, ESPR, and NBTX Company Descriptions

Design Therapeutics NASDAQ:DSGN

$3.97 +0.07 (+1.79%)

Closing price 06/24/2025 04:00 PM Eastern

Extended Trading

$3.97 0.00 (0.00%)

As of 06/24/2025 04:04 PM Eastern

Design Therapeutics, Inc. a biopharmaceutical company, researches, designs, develops, and commercializes small molecule therapeutic drugs for the treatment of genetic diseases in the United States. The company utilizes its GeneTAC platform to design and develop therapeutic candidates for inherited diseases caused by nucleotide repeat expansion. Its lead product candidates for potentially disease-modifying treatment comprises Friedreich Ataxia, a monogenic, autosomal recessive, progressive multi-system disease that affects organ systems dependent on mitochondrial function that brings to neurological, cardiac, and metabolic dysfunction; Myotonic Dystrophy Type-1, a dominantly-inherited, monogenic progressive neuromuscular disease affecting skeletal muscle, heart, brain, and other organs; Fuchs Endothelial Corneal Dystrophy, a genetic eye disease characterized by bilateral degeneration of corneal endothelial cells and progressive loss of vision; and Huntington's Disease, a dominantly inherited, monogenic neurodegenerative disease characterized by movement, cognitive, and psychiatric disorders. Design Therapeutics, Inc. was incorporated in 2017 and is headquartered in Carlsbad, California.

Esperion Therapeutics NASDAQ:ESPR

$1.07 +0.03 (+2.88%)

Closing price 06/24/2025 04:00 PM Eastern

Extended Trading

$1.08 +0.01 (+1.40%)

As of 06/24/2025 05:58 PM Eastern

Esperion Therapeutics, Inc., a pharmaceutical company, develops and commercializes medicines for the treatment of patients with elevated low density lipoprotein cholesterol (LDL-C). Its marketed products include NEXLETOL (bempedoic acid) and NEXLIZET (bempedoic acid and ezetimibe) tablets that are oral, once-daily, non-statin medicines for the treatment of primary hyperlipidemia in adults with heterozygous familial hypercholesterolemia or atherosclerotic cardiovascular disease who require additional lowering of LDL-C. The company's products also include NILEMDO, an ATP Citrate Lyase (ACL) inhibitor that lowers LDL-C and cardiovascular risk by reducing cholesterol biosynthesis and up-regulating the LDL receptors; and NUSTENDI, a bempedoic acid and ezetimibe tablet to treat elevated LDL-C. The company has license and collaboration agreements with Daiichi Sankyo Co. Ltd to; Otsuka Pharmaceutical Co., Ltd; and Daiichi Sankyo Europe GmbH. Esperion Therapeutics, Inc. was incorporated in 2008 and is headquartered in Ann Arbor, Michigan.

InflaRx NASDAQ:IFRX

$0.80 +0.01 (+0.88%)

Closing price 06/24/2025 04:00 PM Eastern

Extended Trading

$0.80 0.00 (-0.38%)

As of 04:03 AM Eastern

InflaRx N.V., a clinical-stage biopharmaceutical company, discovers and develops inhibitors using C5a technology in Germany and the United States. The company's C5a is an inflammatory mediator that is involved in the progression of a variety of autoimmune and other inflammatory diseases. Its lead product candidate is vilobelimab, a novel intravenously delivered first-in-class anti-C5a monoclonal antibody, which completed the Phase III clinical trial for the treatment of hidradenitis suppurativa, a rare and chronic debilitating systemic inflammatory skin disease; for the treatment of anti-neutrophil cytoplasm antibody associated vasculitis, a rare and life-threatening autoimmune disease that is in Phase II trial; to treat pyoderma gangraenosum, a chronic inflammatory skin disorder that is in Phase IIa exploratory study; and for the treatment of PD-1/PD-L1 inhibitor resistant/refractory locally advanced or metastatic cutaneous squamous cell carcinoma that is in Phase II clinical development stage. The company develops INF904, an oral, small molecule drug candidate for the chronic inflammatory and autoimmune diseases; IFX002 that is in pre-clinical development stage for the treatment of chronic inflammation and autoimmune diseases; and Gohibic (vilobelimab) for the treatment of COVID-19 and broader ARDS. It has co-development agreement with Beijing Defengrei Biotechnology Co. Ltd.; and clinical trial collaboration and supply agreement with Merck & Co. Inc. The company was formerly known as Fireman B.V. and changed its name to InflaRx N.V. in 2017. InflaRx N.V. was founded in 2007 and is headquartered in Jena, Germany.

Nanobiotix NASDAQ:NBTX

$4.44 +0.03 (+0.57%)

As of 06/24/2025 03:59 PM Eastern

Nanobiotix S.A., a clinical-stage biotechnology, focuses on developing product candidates for the treatment of cancer and other unmet medical needs. Its lead product candidate is NBTXR3, a sterile aqueous suspension of crystalline hafnium oxide nanoparticles used for the treatment of soft tissue sarcoma, head and neck cancers, liver cancers, prostate cancer, pancreatic cancer, esophageal cancer, rectal cancer, and non-small cell lung cancer. The company has a partnership with Lian Oncology Limited to develop and commercialize NBTXR3 in Greater China, South Korea, Singapore, and Thailand. Nanobiotix S.A. was incorporated in 2003 and is headquartered in Paris, France.

More Stock Comparisions from MarketBeat

More Stock Ideas from MarketBeat

Stock Lists

Low Priced Stocks

Stocks By Exchange

Latest Stock Ideas

Get 30 Days of MarketBeat All Access for Free

Start Your 30-Day Trial

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Compare Stocks

Comparative Price Performance Over Time